Potential antiprostatic performance of novel lanthanide‑complexes based on 5‑nitropicolinic acid García García, Amalia Cristobal Cueto, Pablo Hidalgo, Tania Vitorica-Yrezabal, Iñigo Javier Rodríguez Diéguez, Antonio Horcajada, Patricia Rojas Macías, Sara 5-Nitropicolinic acid Lanthanide Coordination compounds Two new lanthanide-complexes based on the 5-nitropicolinate ligand (5-npic) were obtained and fully characterized. Singlecrystal X-ray diffraction revealed that these compounds are isostructural to a Dy-complex, previously published by us, based on dinuclear monomers link together with an extended hydrogen bond network, providing a final chemical formula of [ Ln2(5-npic)6(H2O)4]·(H2O)2, where Ln = Dy (1), Gd (2), and Tb (3). Preliminary photoluminescent studies exhibited a ligand-centered emission for all complexes. The potential antitumoral activity of these materials was assayed in a prostatic cancer cell line (PC-3; the 2nd most common male cancerous disease), showing a significant anticancer activity (50–60% at 500 μg·mL−1). In turn, a high biocompatibility by both, the complexes and their precursors in human immunological HL-60 cells, was evidenced. In view of the strongest toxic effect in the tumoral cell line provided by the free 5-npic ligand (~ 40–50%), the overall anticancer complex performance seems to be triggered by the presence of this molecule. 2024-07-23T10:59:50Z 2024-07-23T10:59:50Z 2024-05-08 journal article García-García, A., Cristobal-Cueto, P., Hidalgo, T. et al. Potential antiprostatic performance of novel lanthanide-complexes based on 5-nitropicolinic acid. J Biol Inorg Chem 29, 331–338 (2024). [https://doi.org/10.1007/s00775-024-02054-0] https://hdl.handle.net/10481/93400 10.1007/s00775-024-02054-0 eng info:eu-repo/grantAgreement/EC/H2020/897678 http://creativecommons.org/licenses/by/4.0/ open access Atribución 4.0 Internacional Springer Nature